Navigation Links
Tiny antibody fragments raised in camels find drug targets in human breast cancer cells
Date:4/11/2011

A new discovery published online in The FASEB Journal (http://www.fasebj.org) promises to help physicians identify patients most likely to benefit from breast cancer drug therapies. If the compound, called "Nanobody," proves effective in clinical trials, it would represent a significant advance for breast cancer drug therapy because some drugs are effective only in some people. In addition, some drugs have side effects that may cause damage to vital organs, making it more crucial for physicians to get the right treatment to the right patient the first time around.

"What makes Nanobodies so promising is that they are robust, small enough for rapid elimination from the body, and easy to produce at a relatively low cost," said Ilse Vaneycken, M.Sc., a researcher involved in the work.

To make this discovery, Vaneycken and her colleagues started with the target of the therapeutic drugs (HER2) and immunized a dromedary camel to raise special antibodies unique to this species. Next, all unnecessary parts of the camel's antibodies were removed and cloned in bacteria. Of 100 million bacterial clones, the team selected those that produced the 40 Nanobodies that recognized― or bound to―the same site targeted by therapeutic drugs. Of this group, the team screened for compounds that picked out breast cancer cells bearing the genetic tag HER2. Their lead compound did just that, and without blocking access to cancer-killing drugs now in use. Other properties of Nanobodies, such as good expression, stability, and visibility―enabled breast cancer tumors to be stained and seen rapidly―were also exploited.

"The scientists went over the hump to get to the lump so to speak," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This technique not only promises to help doctors target cancer cells with effective drugs today, but to pick out other discrete cancer targets in the future."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related medicine news :

1. Fox Chase clinical trial tests first of its kind antibody
2. Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
3. Antibody Linked to Allergies on the Rise
4. HJF signs distribution agreement for antibody to evaluate prostate cancer
5. Tufts receives patent for antibody treatment against hemolytic uremic syndrome
6. Migraine Tied to Raised Multiple Sclerosis Risk
7. Psoriasis Tied to Raised Heart Risk
8. Kids Raised by Relatives Face Increased Health Risks
9. Frequent Urination at Night Linked to Raised Death Risk
10. Belly-Baring Cheerleaders at Raised Risk of Eating Disorders
11. YAS-A-THON for ThinkCure Hits it Out of the Park: $140,000 Raised, 270,000 Calories Burned!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... United Benefit Advisors (UBA), the nation’s ... to its growing list of Partner Firms. S.S. Nesbitt is headquartered in ... Huntsville and in between. , Harnessing the experience and insights of the agency’s ...
(Date:2/10/2016)... ... 2016 , ... AHRA: The Association for Medical Imaging Management ... will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, ... effectively communicate with their own organizational staff and leadership. , “I am ...
(Date:2/10/2016)... Palm Beach, Florida (PRWEB) , ... February 10, ... ... & Country Club) announced that it has been awarded the prestigious Distinguished Emerald ... the World award program conducted by BoardRoom magazine, one of the most respected ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week ... series of monitor mounts ever. , “Our goal was to develop a product ... install system that we have ever created.” said Darren Hulsey, Product Manager for Workrite ...
(Date:2/10/2016)... ... , ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman ... announcement Monday night, Feb. 8, prior to the evening session of the university’s 80th ... of GO! Camp, has been named director. Gayle McDonald, currently the assistant director of ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016 Urologix, the market leader for ... Benign Prostatic Hyperplasia (BPH), announces new private ownership and ... a medical device industry veteran of more than 20 ... Company.  Plymouth, Minn. ... ThermoTherapy™ and Prostiva® RF Therapy, will continue to be ...
(Date:2/10/2016)... -- A Worldwide Clinical Trials expert will present ... Park Plaza in London , 24-25 February ... future advances for late phase research on Wednesday, 24 Feb ... associate director of project management at Worldwide, will focus on ... and standards in late phase research. --> ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016  Visage ... Pro Medicus Ltd. (ASX: PME), has announced that the ... of Florida (UF) have selected the Visage 7 ... viewer of the Emergent/Critical Care Imaging SIMulation (SIM). ... in Diagnostic Imaging Program (WIDI), a multi-faceted and ...
Breaking Medicine Technology: